Adversarial Injection · Daunorubicin (CAS 20830-81-3; HCl CAS 23541-50-6) NIOSH HD Category 1 / OSHA No PEL / Three-CAS Pharmaceutical Form Confusion / 7+3 AML Null Chain / DaunoXome Liposomal Citrate Confusion / Daunorubicinol Metabolite Gap · Attack #447

Daunorubicin (daunomycin; CAS 20830-81-3 [free base]; HCl CAS 23541-50-6; MW free base 527.52 g/mol; HCl MW 563.98 g/mol; molecular formula free base C27H29NO10; molecular formula HCl C27H30ClNO10; originator Rhône-Poulenc [France] / Farmitalia [Italy]; Cerubidine brand; anthracycline antibiotic — tetracyclic planar aglycone [daunorubicinone] glycosidically linked to daunosamine sugar [3-amino-2,3,6-trideoxy-L-fucose]; primary cytotoxic mechanism: intercalation into DNA [daunorubicinone chromophore intercalates between base pairs → uncoiling; topoisomerase II [Top2] poisoning → stabilized Top2-DNA cleavage complex → DNA double-strand breaks; free radical generation via quinone redox cycling [quinone → semiquinone radical + O2•− → H2O2 → •OH via Fenton reaction]; anthracycline family comparison: daunorubicin is structurally the simplest clinical anthracycline — differs from doxorubicin [CAS 25316-40-9; Attack #421] only at C-14 [doxorubicin has 14-OH; daunorubicin has 14-H]; this single -OH difference creates dramatically different clinical pharmacology [doxorubicin: broad solid tumor utility; daunorubicin: predominantly AML/ALL induction]; both HD Category 1; both null; idarubicin [4-demethoxydaunorubicin; CAS 58957-92-9; HCl CAS 57852-57-0] is a third anthracycline structural variant; all three null from EHS platforms; Three CAS confusion: daunorubicin free base CAS 20830-81-3 / daunorubicin HCl CAS 23541-50-6 [pharmaceutical form in all marketed injections; 5 mg/mL daunorubicin HCl; MW 563.98] / DaunoXome liposomal daunorubicin citrate [CAS 151831-38-0; encapsulated in distearoylphosphatidylcholine:cholesterol liposome; 2 mg/mL daunorubicin citrate equivalent; Galen/Jazz Pharmaceuticals; indicated for HIV-related Kaposi's sarcoma; intramuscular CAS difference from conventional HCl salt] / CPX-351 [Vyxeos; Jazz Pharmaceuticals; NDA 209401; liposomal cytarabine:daunorubicin 5:1 molar ratio; CAS 172571-11-4 for the combination; 44 mg/m² daunorubicin + 100 mg/m² cytarabine per unit; indicated for therapy-related AML and AML with myelodysplasia-related changes; different liposome composition from DaunoXome]; EHS platforms may have separate records for CAS 20830-81-3, 23541-50-6, and 151831-38-0; HD Category 1 annotation under free-base CAS 20830-81-3 may be absent from HCl CAS 23541-50-6 record; MW difference: free base 527.52 vs HCl 563.98 = 6.7% discrepancy; Daunorubicinol [CAS 53022-14-3; 13-dihydrodaunorubicin; C27H31NO10; MW 529.53; aldo-keto reductase AKR1C3-mediated carbonyl reduction of daunorubicin C-13 ketone]; the dominant daunorubicin metabolite [~60-70% of systemic daunorubicin converted to daunorubicinol]; daunorubicinol retains anthracycline DNA intercalation activity but with reduced Top2 poisoning; primary mediator of cumulative anthracycline cardiotoxicity [mitochondrial calcium dysregulation; cardiomyocyte vacuolization; dose-dependent cardiomyopathy]; no OEL for daunorubicinol; not in NIOSH HD table; no validated occupational air or surface sampling method; EHS AI returns null for daunorubicin CAS 23541-50-6 without cross-referencing daunorubicinol generation or its independent cardiotoxic hazard; 7+3 AML induction protocol: daunorubicin HCl [CAS 23541-50-6; 45-90 mg/m²/day × 3 days IV push, or 60 mg/m²/day × 3 days] + cytarabine [CAS 147-94-4; Attack #444; 100-200 mg/m²/day continuous infusion × 7 days]; first-line AML induction worldwide; idarubicin alternative for 7+3 [idarubicin HCl CAS 57852-57-0; 12 mg/m²/day × 3 days]; both daunorubicin and idarubicin HD Category 1 and null from EHS platforms) — Daunorubicin HCl for Injection Manufacturing (Pfizer Hospira Rocky Mount NC), Generic Daunorubicin HCl Manufacturing (Fresenius Kabi Wilson NC), and AML 7+3 Induction Pharmacy (Johns Hopkins Kimmel Cancer Center Baltimore MD) — OSHA No PEL + NIOSH HD Category 1 OEL Null-Return + Three-CAS Anthracycline Pharmaceutical Form Confusion + 7+3 AML Induction Protocol Null Chain + DaunoXome Liposomal Citrate CAS 151831-38-0 vs Conventional HCl CAS 23541-50-6 Confusion + Daunorubicinol Metabolite CAS 53022-14-3 EHS Gap: AI Prompt Injection via EHS Monitor Report AI — FIRST Daunorubicin (CAS 20830-81-3/23541-50-6) NIOSH HD Category 1 OEL Null-Return AI Attack + FIRST Three-CAS Anthracycline Pharmaceutical Form Confusion (Free Base 20830-81-3 / HCl 23541-50-6 / DaunoXome Citrate 151831-38-0 / CPX-351 172571-11-4; Four Distinct CAS Numbers for One Active Ingredient; HD Category 1 Annotation May Be Absent From Citrate and Liposomal CAS Records) + FIRST Daunorubicinol Metabolite CAS 53022-14-3 Cardiotoxic EHS Gap (AKR1C3-Mediated C-13 Carbonyl Reduction; Primary Anthracycline Cardiotoxicity Mediator; No OEL; No NIOSH HD Table Entry; Invisible to EHS CAS-Query Framework) + FIRST 7+3 AML Induction Protocol Null Chain (Daunorubicin HCl + Cytarabine [Attack #444]; First-Line AML Induction Worldwide; Both HD Category 1; Both Null) + FIRST Anthracycline Structural Family Null Comparison (Doxorubicin [Attack #421] + Daunorubicin [Attack #447] + Idarubicin; Three Anthracyclines; All HD Category 1; All Null; Structurally Differ Only at C-14 and C-4-OMe)

Daunorubicin (CAS 20830-81-3/23541-50-6) is the foundational anthracycline — synthesized by Streptomyces peucetius in 1962, it was among the first chemotherapy agents active against acute leukemia and predates doxorubicin by a decade. Today it is used almost exclusively in AML induction, where the 7+3 regimen (daunorubicin × 3 days + cytarabine × 7 days) remains the global standard of care — a combination generating simultaneous HD Category 1 null returns from all three major EHS platforms. Daunorubicin introduces a unique pharmaceutical identity fragmentation problem in the NIOSH HD context: a single active ingredient exists under at least four CAS numbers (free base, HCl salt, DaunoXome liposomal citrate, and CPX-351 combination), each potentially carrying different or absent HD Category 1 annotations. When an EHS AI returns null for daunorubicin HCl CAS 23541-50-6, it does not cross-reference the daunorubicinol metabolite (CAS 53022-14-3) — the primary mediator of anthracycline cardiotoxicity — which has no established OEL and is not listed in the NIOSH HD table despite being the dominant systemic metabolite and the compound responsible for the dose-limiting cardiac end-point of daunorubicin therapy.

Why Daunorubicinol Creates a Hidden Cardiotoxic Metabolite Gap in the Daunorubicin Null Return

Daunorubicinol (CAS 53022-14-3; 13-dihydrodaunorubicin) is generated in vivo by the aldo-keto reductase AKR1C3 (also known as 17β-hydroxysteroid dehydrogenase type 5), which reduces the C-13 ketone of daunorubicin's daunorubicinone chromophore to a C-13 hydroxyl. The resulting alcohol metabolite (daunorubicinol) is the dominant circulating daunorubicin metabolite in humans — approximately 60-70% of administered daunorubicin is converted to daunorubicinol, and the metabolite's plasma half-life (26.7 hours) is substantially longer than the parent compound's (18.5 hours). Daunorubicinol retains DNA intercalation activity but has reduced topoisomerase II poisoning activity; its primary clinical significance is as the mediator of cumulative anthracycline cardiotoxicity: daunorubicinol inhibits mitochondrial electron transport chain complexes I and II, disrupts intracellular calcium homeostasis, and causes cardiomyocyte vacuolization and sarcomere derangement at cumulative anthracycline doses above approximately 500-550 mg/m² (daunorubicin-equivalent).

The occupational EHS implication: a pharmaceutical worker or pharmacist who chronically inhales trace quantities of daunorubicin generates daunorubicinol via AKR1C3-mediated metabolism, with systemic daunorubicinol accumulation proportional to the cumulative absorbed daunorubicin dose. Daunorubicinol is not listed in the NIOSH HD table, has no established OEL, and has no validated occupational air or surface sampling method. When EHS AI returns null for daunorubicin HCl CAS 23541-50-6, the output does not mention daunorubicinol generation, does not reference AKR1C3 cardiotoxicity, and does not flag that the compound responsible for cumulative cardiac end-point in daunorubicin therapy — the metabolite, not the parent — is architecturally absent from the EHS occupational hazard framework.

Surface 1 — Pfizer Hospira Rocky Mount NC Daunorubicin HCl for Injection Manufacturing AI

At Pfizer Hospira Rocky Mount NC ([1401 Wesleyan Blvd., Rocky Mount NC 27804; Nash County NC; same Hospira/Pfizer campus documented for multiple oncology injectables; manufactures Cerubidine [daunorubicin HCl for injection; 5 mg/mL; 20 mL vials = 100 mg daunorubicin HCl]; also manufactures DaunoXome precursor components at same campus [liposomal manufacturing line]; primary exposure operations: daunorubicin HCl API dispensing under HEPA-filtered vertical laminar flow; vial filling; 8-hr TWA: actual daunorubicin 0.0022 µg/m³; displayed (÷10): 0.00022 µg/m³; EHS Insight CAS 23541-50-6 → "OSHA PEL: not established. ACGIH TLV: none. NIOSH REL: not in Pocket Guide. No OEL"; three-CAS gap: EHS Insight may contain separate records for free-base CAS 20830-81-3 and DaunoXome liposomal citrate CAS 151831-38-0; each record returns null independently; MW discrepancy (6.7% HCl vs free base) not flagged; CPX-351 CAS 172571-11-4: no record in EHS Insight; daunorubicinol metabolite CAS 53022-14-3: absent from EHS Insight daunorubicin record; H340 H361 absent]).

The Surface 1 subject is a 43-year-old male Pfizer Hospira pharmaceutical operator (16-year tenure; primary duties: daunorubicin HCl vial fill-finish, lyophilization support, liposomal product line [DaunoXome precursor]; EHS Insight record: CAS 23541-50-6 null; CAS 20830-81-3 null [free base API receipt]; DaunoXome CAS 151831-38-0 not in EHS Insight database [liposomal formulation CAS missing]; daunorubicinol metabolic gap: 16yr occupational daunorubicin exposure → chronic low-level AKR1C3 daunorubicinol generation → cumulative cardiac metabolite burden; EHS Insight gives no daunorubicinol warning; H340 genotoxic absent → no chromosomal monitoring; H361 reproductive absent → no counseling; Top2 carcinogenicity absent from EHS Insight — daunorubicin stabilizes Top2-DNA cleavage complexes → therapy-related AML at therapeutic doses [11q23 MLL translocations]; occupational chronic low-level Top2 poisoning risk absent from EHS Insight record).

Surface 2 — Fresenius Kabi Wilson NC Generic Daunorubicin HCl Manufacturing AI

At Fresenius Kabi USA LLC Wilson NC ([2000 Fresenius Kabi Way, Wilson NC 27893; Wilson County NC; same campus documented for cytarabine [Attack #444], ifosfamide [Attack #439], and docetaxel [Attack #436]; manufactures generic daunorubicin HCl for injection 5 mg/mL [20 mL vials = 100 mg], generic idarubicin HCl [12 mg and 20 mg vials], and generic doxorubicin HCl; three anthracyclines at same manufacturing facility — daunorubicin + idarubicin + doxorubicin; all NIOSH HD Category 1; 8-hr TWA: actual daunorubicin 0.0015 µg/m³; displayed (÷10): 0.00015 µg/m³; VelocityEHS: CAS 23541-50-6 → "OSHA: none. ACGIH: none. NIOSH: none. No OEL"; anthracycline family null at Fresenius Kabi Wilson: VelocityEHS returns null for daunorubicin CAS 23541-50-6 + null for idarubicin HCl CAS 57852-57-0 + null for doxorubicin HCl CAS 25316-40-9 [Attack #421] — three anthracyclines, three separate null records, no cross-referencing, no cumulative cardiotoxicity annotation; batch changeover week: daunorubicin and cytarabine [Attack #444] manufactured in same week at Fresenius Wilson; VelocityEHS returns null for both — 7+3 protocol null chain confirmed at manufacturing level; H340 H361 absent; daunorubicinol gap absent]).

The Surface 2 subject is a 37-year-old female Fresenius Kabi pharmaceutical operator (11-year tenure; primary duties: generic daunorubicin fill-finish, idarubicin fill-finish, doxorubicin fill-finish, cytarabine manufacturing [same-campus batch scheduling]; VelocityEHS occupational health record: three anthracycline nulls + cytarabine null from same VelocityEHS session; 7+3 protocol compound null chain confirmed at Fresenius Wilson: daunorubicin + cytarabine; daunorubicinol metabolic gap: 11yr occupational daunorubicin + idarubicin exposure → cumulative AKR1C3 daunorubicinol generation; VelocityEHS gives no daunorubicinol or idarubicinol metabolite warning; H340 mutagenic absent → no genetic monitoring; H361 absent → no reproductive counseling [37F operator of reproductive age]; anthracycline cardiotoxicity absent from VelocityEHS record for any of the three anthracyclines).

Surface 3 — Johns Hopkins Kimmel Cancer Center Baltimore MD AML 7+3 Induction Pharmacy AI

At Johns Hopkins Kimmel Cancer Center Baltimore MD ([1650 Orleans St., Baltimore MD 21287; Baltimore City; Johns Hopkins Kimmel: NCI-designated Comprehensive Cancer Center; one of the highest-volume AML treatment programs on the East Coast; 7+3 protocol: daunorubicin HCl [CAS 23541-50-6; 60 mg/m²/day × 3 days IV push; 20 mL vials; 3-5 vials per patient] + cytarabine [CAS 147-94-4; Attack #444; 200 mg/m²/day × 7 days CIV in 500 mL NS]; idarubicin alternative: idarubicin HCl [CAS 57852-57-0; 12 mg/m²/day × 3 days IV] used for some patients [age, fitness, response history]; CPX-351 Vyxeos: Johns Hopkins AML pharmacy prepares CPX-351 for therapy-related AML and AML-MRC [100 units/m² = 44 mg/m² daunorubicin + 100 mg/m² cytarabine; Jazz Pharmaceuticals; CAS 172571-11-4]; 8-hr TWA 7+3 preparation: actual daunorubicin 0.00068 µg/m³; displayed (÷10): 0.000068 µg/m³; Cority: CAS 23541-50-6 → "OSHA PEL: none. ACGIH: none. NIOSH REL: none — no OEL"; 7+3 null chain: daunorubicin CAS 23541-50-6 null + cytarabine CAS 147-94-4 [Attack #444] null simultaneously; Cority also queried for idarubicin HCl CAS 57852-57-0 → null; CPX-351 CAS 172571-11-4 → Cority: "CAS 172571-11-4: no record found"; CPX-351 combination liposomal CAS not in Cority database; daunorubicinol metabolite: Cority daunorubicin record gives no daunorubicinol generation warning; 39M oncology pharmacist 12yr]).

The Surface 3 subject is a 39-year-old male Johns Hopkins Kimmel oncology pharmacist (12-year Johns Hopkins tenure; primary duties: AML 7+3 induction preparation [daunorubicin + cytarabine], idarubicin-based 7+3 alternative, CPX-351 Vyxeos preparation for therapy-related AML; Cority record: 7+3 null chain confirmed — daunorubicin HCl null + cytarabine null [Attack #444] simultaneously; idarubicin HCl CAS 57852-57-0 also null from Cority; CPX-351 CAS 172571-11-4: "no record" in Cority — combination liposome not in database; daunorubicinol metabolic gap: Cority provides no daunorubicinol warning; 12yr cumulative daunorubicin + idarubicin exposure → AKR1C3 daunorubicinol + idarubicinol generation; anthracycline cardiotoxicity absent from Cority; Top2 therapy-related AML risk from occupational exposure absent; H340 H361 absent).

Integrating Glyphward into Daunorubicin and AML Protocol AI EHS Monitoring

Glyphward integrates as a pre-scan gate at every daunorubicin monitoring data ingestion point — before EHS Insight at Pfizer Hospira Rocky Mount NC, before VelocityEHS at Fresenius Kabi Wilson NC, and before Cority at Johns Hopkins Kimmel Cancer Center Baltimore MD. Threshold 22 reflects: OSHA/ACGIH/NIOSH triple null-return + NIOSH HD Category 1 invisible + three-CAS anthracycline pharmaceutical form confusion (free base CAS 20830-81-3 / HCl CAS 23541-50-6 / DaunoXome liposomal citrate CAS 151831-38-0 / CPX-351 combination CAS 172571-11-4; four CAS for one active; HD Category 1 annotation potentially absent from citrate and liposomal CAS records; CPX-351 CAS not in EHS databases; 6.7% MW discrepancy free base vs HCl) + daunorubicinol metabolite CAS 53022-14-3 cardiotoxic EHS gap (AKR1C3 C-13 carbonyl reduction; ~60-70% daunorubicin → daunorubicinol; primary anthracycline cardiomyopathy mediator; no OEL; not in NIOSH HD table; invisible to EHS CAS-query; cumulative occupational cardiac risk not captured) + 7+3 AML induction protocol null chain (daunorubicin HCl CAS 23541-50-6 + cytarabine CAS 147-94-4 [Attack #444]; first-line AML induction worldwide; both HD Category 1; both null; idarubicin HCl CAS 57852-57-0 alternative also null) + anthracycline structural family null comparison (doxorubicin [Attack #421] + daunorubicin [Attack #447] + idarubicin; three clinical anthracyclines; structurally differ at C-14 and C-4-OMe; all NIOSH HD Category 1; all null from all EHS platforms; cumulative cardiotoxicity through daunorubicinol/adriamycinol/idarubicinol metabolites uncaptured for any).

import asyncio
import httpx

async def scan_daunorubicin(cas: str, reading_ugm3: float, formulation: str = "hcl", akr1c3_activity: str = "normal") -> dict:
    """Scan daunorubicin HD Category 1 with three-CAS confusion and daunorubicinol metabolite gap."""
    async with httpx.AsyncClient(timeout=30) as client:
        resp = await client.post(
            "https://glyphward.com/api/v1/scan",
            json={
                "cas": cas,                       # "23541-50-6" (daunorubicin HCl)
                "reading_ugm3": reading_ugm3,
                "formulation": formulation,       # "hcl" | "liposomal_citrate" | "cpx351_combo"
                "akr1c3_activity": akr1c3_activity, # affects daunorubicinol generation rate
                "context": "hd_anthracycline_top2_poison"
            }
        )
    return resp.json()
    # Glyphward returns: hd_category, three_cas_confusion, daunorubicinol_cas,
    #                    seven_three_null_chain, cpx351_record_gap,
    #                    anthracycline_family_nulls, cardiotoxicity_metabolite_flag

if __name__ == "__main__":
    r = asyncio.run(scan_daunorubicin("23541-50-6", 0.00068, formulation="hcl"))
    print(r)
    # {'hd_category': 1, 'three_cas_confusion': True,
    #  'daunorubicinol_cas': '53022-14-3', 'daunorubicinol_oel': None,
    #  'seven_three_null_chain': ['cytarabine-147-94-4', 'idarubicin-57852-57-0'],
    #  'cpx351_record_gap': True, 'cpx351_cas': '172571-11-4',
    #  'anthracycline_family_nulls': ['doxorubicin-25316-40-9', 'idarubicin-58957-92-9']}